105 related articles for article (PubMed ID: 27919945)
41. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma.
Zhou SL; Dai Z; Zhou ZJ; Wang XY; Yang GH; Wang Z; Huang XW; Fan J; Zhou J
Hepatology; 2012 Dec; 56(6):2242-54. PubMed ID: 22711685
[TBL] [Abstract][Full Text] [Related]
42. Large-scale production of N-acetyllactosamine through bacterial coupling.
Endo T; Koizumi S; Tabata K; Kakita S; Ozaki A
Carbohydr Res; 1999 Mar; 316(1-4):179-83. PubMed ID: 10420596
[TBL] [Abstract][Full Text] [Related]
43. Hepatoma-derived growth factor/nucleolin axis as a novel oncogenic pathway in liver carcinogenesis.
Chen SC; Hu TH; Huang CC; Kung ML; Chu TH; Yi LN; Huang ST; Chan HH; Chuang JH; Liu LF; Wu HC; Wu DC; Chang MC; Tai MH
Oncotarget; 2015 Jun; 6(18):16253-70. PubMed ID: 25938538
[TBL] [Abstract][Full Text] [Related]
44. Galactose breath testing distinguishes variant and severe galactose-1-phosphate uridyltransferase genotypes.
Berry GT; Singh RH; Mazur AT; Guerrero N; Kennedy MJ; Chen J; Reynolds R; Palmieri MJ; Klein PD; Segal S; Elsas LJ
Pediatr Res; 2000 Sep; 48(3):323-8. PubMed ID: 10960497
[TBL] [Abstract][Full Text] [Related]
45. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
46. Eukaryotic elongation factor-1α 2 knockdown inhibits hepatocarcinogenesis by suppressing PI3K/Akt/NF-κB signaling.
Qiu FN; Huang Y; Chen DY; Li F; Wu YA; Wu WB; Huang XL
World J Gastroenterol; 2016 Apr; 22(16):4226-37. PubMed ID: 27122673
[TBL] [Abstract][Full Text] [Related]
47. The expression and effects the CABYR-c transcript of CABYR gene in hepatocellular carcinoma.
Li H; Fang L; Xiao X; Shen L
Bull Cancer; 2012 Mar; 99(3):E26-33. PubMed ID: 22285430
[TBL] [Abstract][Full Text] [Related]
48. [Abnormal expression of insulin-like growth factor-II and intervening of its mRNA transcription in the promotion of HepG2 cell apoptosis].
Dong ZZ; Yao M; Qian J; Yan XD; Chen J; Yan MJ; Yao NH; Yao DF
Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(12):892-6. PubMed ID: 23863671
[TBL] [Abstract][Full Text] [Related]
49. The N314D polymorphism of galactose-1-phosphate uridyl transferase does not modify the risk of ovarian cancer.
Fung WL; Risch H; McLaughlin J; Rosen B; Cole D; Vesprini D; Narod SA
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):678-80. PubMed ID: 12869412
[TBL] [Abstract][Full Text] [Related]
50. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
51. Engineering CHO cells galactose metabolism to reduce lactate synthesis.
Jiménez N; Martínez VS; Gerdtzen ZP
Biotechnol Lett; 2019 Jul; 41(6-7):779-788. PubMed ID: 31065855
[TBL] [Abstract][Full Text] [Related]
52. Cotranscription and intergenic splicing of human galactose-1-phosphate uridylyltransferase and interleukin-11 receptor alpha-chain genes generate a fusion mRNA in normal cells. Implication for the production of multidomain proteins during evolution.
Magrangeas F; Pitiot G; Dubois S; Bragado-Nilsson E; Chérel M; Jobert S; Lebeau B; Boisteau O; Lethé B; Mallet J; Jacques Y; Minvielle S
J Biol Chem; 1998 Jun; 273(26):16005-10. PubMed ID: 9632650
[TBL] [Abstract][Full Text] [Related]
53. Metabolic effects of galactose on human HepG2 hepatoblastoma cells.
Davit-Spraul A; Pourci ML; Soni T; Lemonnier A
Metabolism; 1994 Aug; 43(8):945-52. PubMed ID: 8052150
[TBL] [Abstract][Full Text] [Related]
54. Direct and maternal aspects of the risk of cataract with partial disorders of galactose metabolism.
Winder AF; Fielder AR; Mount JN; Menzies JS
Clin Genet; 1985 Sep; 28(3):199-206. PubMed ID: 4064358
[TBL] [Abstract][Full Text] [Related]
55. Discovery of novel inhibitors of human galactokinase by virtual screening.
Hu X; Zhang YQ; Lee OW; Liu L; Tang M; Lai K; Boxer MB; Hall MD; Shen M
J Comput Aided Mol Des; 2019 Apr; 33(4):405-417. PubMed ID: 30806949
[TBL] [Abstract][Full Text] [Related]
56. Two siblings with galactose mutarotase deficiency: Clinical differences.
Yazici H; Canda E; Altınok YA; Ucar SK; Coker M
JIMD Rep; 2022 Jan; 63(1):25-28. PubMed ID: 35028268
[TBL] [Abstract][Full Text] [Related]
57. Structure-Based Optimization of Small Molecule Human Galactokinase Inhibitors.
Liu L; Tang M; Pragani R; Whitby FG; Zhang YQ; Balakrishnan B; Fang Y; Karavadhi S; Tao D; LeClair CA; Hall MD; Marugan JJ; Boxer M; Shen M; Hill CP; Lai K; Patnaik S
J Med Chem; 2021 Sep; 64(18):13551-13571. PubMed ID: 34491744
[TBL] [Abstract][Full Text] [Related]
58. Suppression of polarity in the gal operon by ultraviolet irradiation.
Fassler JS; Tessman I
J Bacteriol; 1980 Dec; 144(3):1205-7. PubMed ID: 7002912
[TBL] [Abstract][Full Text] [Related]
59. Effect of galactose on interaction of N-(2-hydroxypropyl)methacrylamide copolymers with hepatoma cells in culture: preliminary application to an anticancer agent, daunomycin.
O'Hare KB; Hume IC; Scarlett L; Chytrý V; Kopecková P; Kopecek J; Duncan R
Hepatology; 1989 Aug; 10(2):207-14. PubMed ID: 2545589
[TBL] [Abstract][Full Text] [Related]
60. A one-pot enzymatic approach to the O-fluoroglucoside of N-methylanthranilate.
Caputi L; Rejzek M; Louveau T; O'Neill EC; Hill L; Osbourn A; Field RA
Bioorg Med Chem; 2013 Aug; 21(16):4762-7. PubMed ID: 23806835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
